Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYK8MV)

Drug Name
Melanotetan II Drug Info
Synonyms
Monorden; UNII-I60EH8GECX; I60EH8GECX; CHEMBL414883; CHEBI:556075; (1aR,2Z,4E,14R,15aR)-8-chloro-9,11-dihydroxy-14-methyl-1a,14,15,15a-tetrahydro-6H-oxireno[e][2]benzoxacyclotetradecine-6,12(7H)-dione; Monorderne; RDC; C18H17ClO6; Radisicol; Radicolol; Monorden A; RHI-12648; Microlactone, 1; 3cgy; NSC-294404; 4egk; 2wer; NSC 294404; 2zbk; 1bgq; (+)-Monorden A; Radicicol R 2146; 2q8i; SCHEMBL868832; BDBM15361; MolPort-003-959-447; HMS3648C16; BDBM227589; 6H-Oxireno(e)(2)benzoxacyclotetradecin-6,12(7H)-dione, 8-chlor
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Preclinical [1]
Sexual dysfunction HA00-HA01 Preclinical [1]
Type-2 diabetes 5A11 Preclinical [1]
Cross-matching ID
TTD Drug ID
DMYK8MV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Melanocortin receptor 4 (MC4R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methylnaltrexone bromide DMZTGN2 Opioid-induced constipation DB32.1 Approved [1]
Bremelanotide DM20LIM Hypoactive sexual desire dysfunction HA00 Approved [2]
Setmelanotide DMPVRN9 Obesity 5B81 Approved [3]
Amylin DMWDEN0 N. A. N. A. Phase 4 [4]
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [1]
PMX-53 DMZUAJ4 Atopic dermatitis EA80 Phase 2 [5]
PF-446687 DML38VU Female sexual arousal dysfunction HA01.1 Phase 2 [6]
AP-1030 DMBGA35 Metabolic disorder 5C50-5D2Z Phase 1/2 [7]
PF-07258669 DM3CJ5N Malnutrition 5B50-5B71 Phase 1 [8]
PT-14 DMYM9JL Erectile dysfunction HA01.1 Discontinued in Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Melanocortin receptor 3 (MC3R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MT-II DMKT1DA Female sexual arousal dysfunction HA01.1 Investigative [10]
C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2 DMX7IVO Discovery agent N.A. Investigative [11]
Ac-YRMEHdFRWG-NH2 DMN2UKC Discovery agent N.A. Investigative [12]
C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2 DMM19SJ Discovery agent N.A. Investigative [11]
C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2 DMSIGJW Discovery agent N.A. Investigative [11]
C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2 DMUESCH Discovery agent N.A. Investigative [11]
Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2 DMVQ4KG Discovery agent N.A. Investigative [12]
C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 DMD6OW4 Discovery agent N.A. Investigative [13]
AEKKDEGPYRMEHFRWGSPPKD DMZ8SV3 Discovery agent N.A. Investigative [12]
Ac-YRMEHdFRWGSPPKD-NH2 DMDH5B3 Discovery agent N.A. Investigative [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melanocortin receptor 3 (MC3R) TTNI91K MC3R_HUMAN Agonist [1]
Melanocortin receptor 4 (MC4R) TTD0CIQ MC4R_HUMAN Agonist [1]

References

1 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
5 Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
6 Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole. Neuropsychopharmacology. 2015 Jul;40(8):1856-65.
7 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
8 Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite Loss. J Med Chem. 2023 Mar 9;66(5):3195-3211.
9 The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014 Feb;48(1):47-51.
10 Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat. Eur J Pharmacol. 1999 Aug 13;378(3):249-58.
11 Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
12 Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
13 Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.